positions available now

Category Archives: PBS

Relating to the Australian Pharmaceutical Benefits Scheme

Dr Greg Pearce – Time to support biosimilars

Dr Greg Pearce, from our Regulatory Services team, has written a follow-up article for Pharma in Focus on biosimilars. Dr Pearce’s first article focussed on the challenges biosimilars pose for the Australian medicines industry. This second article looks at the … Continue reading

Posted in Life Sciences Industry, PBS, Regulatory Services | Tagged , | Comments Off on Dr Greg Pearce – Time to support biosimilars

Pricing uncertainty within the Pharmaceutical Benefits Scheme

Recent years have seen an active attempt to control Pharmaceutical Benefits Scheme (PBS) costs. Price disclosure and mandatory price cuts upon formulary transition have ensured prices of pharmaceuticals (especially generics) continue to tumble. Yet despite the use of these tools, … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , | Comments Off on Pricing uncertainty within the Pharmaceutical Benefits Scheme

Defining value in the MBS Review

In May 2015 the Federal Government announced a review of the Medicare Benefits Schedule (MBS) with a view to bringing the MBS up-to-date and increase the value derived from the more than 5,700 listed items. The announcement of this review … Continue reading

Posted in Market Access, MBS, Medicare Benefits Schedule, MSAC, PBAC, PBS | Tagged , , , , , , | Comments Off on Defining value in the MBS Review

Is nothing safe from price reduction?

As of 1 April 2016, all F1 medicines that have been on the PBS for five years will take a 5% price cut. Originator brands will be removed from the weighted average disclosed price (WADP) calculations from the cycle commencing … Continue reading

Posted in Life Sciences Industry, Market Access, PBS | Tagged | Comments Off on Is nothing safe from price reduction?

Is it possible to manage PBS Managed Entry Schemes?

Flash back to 1st January 2011 and the Department of Health introduced a unique market access route for innovative medicines to be listed on the PBS: the Managed Entry Scheme. The original framework for the introduction of a PBS Managed … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Comments Off on Is it possible to manage PBS Managed Entry Schemes?

Top 5 – Health in the 2014 Budget

Health has featured strongly in the Abbott Government’s first budget, but not as expected… 1. No PBS Pricing Reforms The anticipated PBS pricing reforms were absent in last week’s budget despite the recommendations of the Commission of Audit for the … Continue reading

Posted in Federal Budget, Life Sciences Industry, PBS | Tagged , , , | Comments Off on Top 5 – Health in the 2014 Budget

PBS off the chopping block… for now

The pharmaceutical sector’s response to the Abbott Government’s first Budget seems to have been one of tentative collective relief, with the anticipated PBS pricing reforms conspicuously absent. However this relief may be short-lived as further PBS reforms may still proceed … Continue reading

Posted in Federal Budget, PBS | Tagged , , , , | Comments Off on PBS off the chopping block… for now

Budget 2013 – A changing PBS operating environment

For many Eye Spy readers, hearing no price related changes to the PBS was the best possible outcome of the 2013 Budget. A momentary sigh of relief, but upon closer inspection we see that the operating environment for medicines is changing in Australia despite repeated calls for certainly and predictability. Continue reading

Posted in Federal Budget, Life Sciences Industry, Market Access, PBS | Tagged , , , | Comments Off on Budget 2013 – A changing PBS operating environment

Top 5 – Health Items in the 2013 Budget

We look a little deeper into the Budget papers to find the Top 5 Health announcements. Continue reading

Posted in Federal Budget, PBS, TGA | Tagged | Comments Off on Top 5 – Health Items in the 2013 Budget

People Trends – Turnover at the top reflects industry broadly

In a media release last month, Medicines Australia announced the resignation of its Board Chair, Mark Masterson. When we consider the recent turnover of MA board members does this turnover at the top reflect what is going on in the industry more broadly? Continue reading

Posted in Life Sciences Industry, PBS | Tagged | Comments Off on People Trends – Turnover at the top reflects industry broadly
Copyright © 2014 Commercial Eyes